Bracco Imaging, a global specialist in contrast media and solutions for medical imaging, is delighted to announce that Gadopiclenol (marketed as Vueway® by Bracco) has been honored with the JFR* 2024 Innovation Award in the Jury’s Favorite category.
This contrast agent represents a major advance in the field of magnetic resonance imaging (MRI).
Gadopiclenol is distinguished by its high relaxivity and high stability, providing images of equivalent quality to the macrocyclic gadolinium contrast agents currently available on the market, while using lower dose of gadolinium than those approved for general-purpose gadolinium-based contrast agents (indeed, a dose of 0.05 mmol/kg is sufficient, compared to 0.1 mmol/kg for most of the other macrocyclic gadolinium contrast agents).
Indicated for adults and children 2 years of age and older, Gadopiclenol improves the detection and visualization of conditions associated with disruption of the blood-brain barrier (BBB) and/or abnormal vascularization in:
- the brain, spine, and other associated tissues of the central nervous system (CNS);
- the liver, kidney, pancreas, breast, lung, prostate and musculoskeletal system (Vueway,
gadopiclenol (europa.eu).
Thanks to its efficacy, safety and the use of lower-doses, Gadopiclenol exemplifies Bracco’s commitment to medical innovation and environmental responsibility providing a cutting-edge solution for medical imaging while reducing the ecological footprint of MRI scans.
The Marketing Authorization (MA) for (Gadopiclenol) was granted to Bracco and Guerbet by the European Commission on December 7, 2023, following approval by the FDA in September 2022. Gadopiclenol is marketed independently by Bracco and Guerbet.
The award ceremony will take place on October 6 at 12:15 p.m., during the Francophone Days of Radiology at the Palais des Congrès in Paris.
Fulvio Renoldi Bracco, CEO, and all Bracco Imaging employees thank the JFR 2024 jury for this prestigious recognition and reaffirm their commitment to pursuing innovation in medical imaging for the benefit of patients and healthcare professionals.